MGMT and glioblastoma: In this case, the status of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, which is a very powerful predictor of response to TMZ for newly diagnosed GBM patients, with a PFS difference of approximately 7 months between “methylated” and “unmethylated” patients, [28] should have been taken into account.